Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

ParaALPHA

Financiado

Paracrine signalling in alpha cells and the integration of mechanisms that contr...

Paracrine signalling in alpha cells and the integration of mechanisms that control glucagon secretion Diabetes is a common disease affecting millions of patients world-vide. The disease is characterised by hyperglycaemia, caused by reduced insulin signalling and release. Recent findings suggest that the hormone glucagon also plays... ver más

31/03/2028

UCPH

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

KOBENHAVNS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-12-16

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2022-STG: ERC STARTING GRANTS

I+D

Cerrada hace 2 años

0% 100% 100%

1 Participantes

UCPH

1.66M€ | Lider

Proyectos interesantes

SAF2017-84708-R REGULACION DE LA ADAPTACION Y PROLIFERACION DE CELULAS BETA... 109K€ Cerrado

PID2019-110496RB-C21 REGULACION PARACRINA MEDIADA POR IDE DE LA FUNCION DE LAS CE... 109K€ Cerrado

SAF2016-77871-C2-1-R PAPEL DE INSULIN DEGRADING ENZYME (IDE) EN LA HIPERGLUCAGONE... 169K€ Cerrado

PID2020-117294RB-I00 RELACION ENTRE ERALPHA, ERBETA Y GPER EN LAS CELULAS BETA DE... 369K€ Cerrado

BES-2009-013188 EFECTOS A CORTO Y LARGO PLAZO DE LA ACTIVACION DE LOS RECEPT... 43K€ Cerrado

EEBB-I-12-04570 EFECTOS A CORTO Y LARGO PLAZO DE LA ACTIVACION DE LOS RECEPT... 7K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 63 meses Fecha Inicio: 2022-12-16
Fecha Fin: 2028-03-31

Líder del proyecto

KOBENHAVNS UNIVERSITET

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto Diabetes is a common disease affecting millions of patients world-vide. The disease is characterised by hyperglycaemia, caused by reduced insulin signalling and release. Recent findings suggest that the hormone glucagon also plays a critical role. Glucagon is a counteregulatory hormone released form alpha cells in pancreatic islets, to increase hepatic glucose production. Diabetic and obese patients suffer from hyperglucagonaemia, which leads to inappropriate hepatic glucose production. Glucagon secretion is regulated by intrinsic and paracrine mechanisms. The intrinsic regulation rely on the effect of glucose on metabolism and the paracrine on secretion of hormones from neighbouring beta and delta cells. Paracrine signalling form insulin and somatostatin inhibits glucagon secretion through activation of Protein kinase B and inhibition of protein kinase A leading to lower electrical and exocytotic activity. Both kinases regulate transcription and metabolism in other tissues. I suggest that paracrine signalling also affect alpha cell metabolism to regulate glucagon secretion. My recent work show that alpha cells rely on fatty acids for ATP production and that the mechanism by which glucose inhibits glucagon secretion requires glucose to lower fatty acid oxidation. In this project, I will 1) investigate whether insulin and somatostatin signalling regulate metabolism and ATP production in alpha cells, 2) identify the underlying kinase signalling, and 3) explore the role of hyperglucagonaemia in diabetes. To understand the effect of insulin and somatostatin on alpha cell function and glucagon secretion, I will use dynamic measurements of kinase signalling, ATP levels, membrane potential and calcium in mouse and human islets. Combining this with genetically modified animal models, we will have the unique opportunity to study if dysfunction of both paracrine and intrinsic regulation of glucagon secretion is required for the development of hyperglucagonaemia in diabetes.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores